This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with Hemophilia and Hepatitis C (with and without HIV co-infection) are being treated with latest generation of Pegylated Interferon plus Ribavirin for 48 weeks. The viral response is being measured at multiple time points during the first 2 weeks of treatment so that we can understand factors associated with early response. In addition, we are studying how the body's immune system contributes to viral clearance. We believe that viral mutations play a key role in treatment outcome and are using sophisticated methods to study the selection of mutants over time.
Showing the most recent 10 out of 502 publications